+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 70Years
All Genders
ID05665140

Personalized Phase II Study of Isatuximab with Lenalidomide, Bortezomib, and Dexamethasone Compared to Standard High-Dose Melphalan Therapy for Low-Risk Newly Diagnosed Multiple Myeloma Patients

Led by University Hopsital Schleswig Holstein Campus Lübeck · Updated on 2024-12-11

100

Participants Needed

6

Research Sites

61 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating personalized first-line therapy approaches for patients with newly diagnosed, low-risk multiple myeloma who are eligible for stem cell transplant. This trial explores whether some patients can safely avoid high-dose melphalan chemotherapy, which is commonly used but associated with significant side effects and risks, including infections and secondary cancers. The study aims to determine if an intensified induction therapy alone could be sufficient for these patients based on gene expression and disease staging, potentially reducing toxicity and improving outcomes. Participants are randomly assigned to one of two treatment groups. One group receives three cycles of induction therapy with isatuximab, bortezomib, lenalidomide, and dexamethasone I-VRD, followed by standard high-dose melphalan chemotherapy and autologous stem cell transplant, then maintenance therapy with isatuximab and lenalidomide. The other group receives six cycles of the I-VRD regimen without upfront high-dose melphalan, followed by the same maintenance therapy. Treatment includes carefully scheduled drug doses, stem cell mobilization, and apheresis where applicable. Throughout the study, participants undergo evaluations including bone marrow assessments, imaging, and laboratory tests to monitor response and disease progression. The main measure is the rate of complete remission combined with minimal residual disease negativity at week 40 after starting induction. Secondary measures include progression-free survival, overall survival, toxicity, and quality of life assessed at multiple time points. Participants adherence and safety are closely monitored during treatment and follow-up until the studys end in 2028.

CONDITIONS

Brief Title

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Research Team

C

Cyrus Khandanpour, Prof. Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here